Rodman & Renshaw Cuts Alimera (ALIM) to Market Perform
Tweet
Share
E-mailGet Alerts ALIM Hot Sheet
Price: $5.54 --0%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Rodman & Renshaw's Suraj Kalia downgraded shares of Alimera Sciences (NASDAQ: ALIM) from Market Outperform to Market Perform in a mid-day research note Monday.
Alimera shares are down nearly 12 percent this afternoon following a 73 percent decline on Friday amid an FDA decision on the company's ILUVIEN NDA.
The stock was also downgraded at Citi and Cowen earlier.
For an analyst ratings summary and ratings history on Alimera Sciences click here. For more ratings news on Alimera Sciences click here.
Alimera shares are down nearly 12 percent this afternoon following a 73 percent decline on Friday amid an FDA decision on the company's ILUVIEN NDA.
The stock was also downgraded at Citi and Cowen earlier.
For an analyst ratings summary and ratings history on Alimera Sciences click here. For more ratings news on Alimera Sciences click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Stellantis NV (STLA:IM) (STLA) to Reduce
- China Renaissance Downgrades Trip.com Group Limited (TCOM) to Hold
- Roblox falls 4% in pre-market as Wells Fargo bookings caution reasserts
Create E-mail Alert Related Categories
DowngradesRelated Entities
Citi, Rodman & Renshaw, Cowen & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
